CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5 enrolled / 5 target
Drug / intervention
Moderatodevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05345925
NCT05345925N/ACompletedUpdate Overdue (0.1/mo)Completion was 31mo ago

Pressure-Volume (PV) Measurements for Evaluating Cardiac Parameters Using BackBeat Medical's Cardiac Neuromodulation Therapy (CNT) Pacing Signals in Different Physiological Pacing Sites: An Acute Study

BackBeat Medical Inc·interventional·Posted Apr 26, 2022·Updated Jun 22, 2026

In Brief

A clinical study evaluating Moderato for Bradycardia and A-V Block. Completed, enrolled 5 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

In a multicenter non-randomized acute setting, eligible subjects requiring implant or replacement of an IPG (pacemaker, ICD, CRT-P, CRT-D) will be instrumented to study the effect of CNT from different locations in the RV. CNT effects on BP will be evaluated with a PV conductance catheter in the LV, and with optional BP catheters in the aorta and/or RV. CNT will be delivered by externally by the BackBeat Moderato System IPG. Abbreviations: CNT, Cardiac Neuromodulation Therapy; IPG, Implanted Pulse Generator; ICD, Implanted Cardiac Defribillator; CRT-P or D, Cardiac Resynchronisation Therapy-Pacemaker or Defibrillator; RV, Right Ventricle; LV, Left Ventricle; BP, Blood Pressure

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPoland
CollaboratorsCD Leycom

Timeline

N/ACompletedFinished
2023202420252026
First PostedApr 26, 2022
Enrollment StartMay 19, 2023
Primary CompletionNov 11, 2023
Study CompletionNov 14, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.2 years ago

Arms & Interventions

Experimental groupexperimental

Eligible subjects instrumented for CNT testing

Device: Moderato

Interventions

Moderatodevice

Several algorithms comprising CNT will be delivered by the Moderato Implantable Pulse Generator. Each application will last approximately 3 min with 2 minutes baseline (regular pacing) between them. Hence, each subject will serve as its own control (during pacing) and test (during CNT application). Furthermore, the average control value for the whole group will be compared with the average test values of CNT algorithms at the different ventricular lead locations for efficacy assessments. Stratification of subjects by initial hemodynamic parameters (such as Ejection Fraction, for example) would be possible depending on the total number of subjects in each group.